Neuralink Clinical Trials — Complete Analysis of the N1 Implant Program Through 2026
Comprehensive tracking of Neuralink's clinical trials from first human implant through third patient, FDA Breakthrough Device designation for speech restoration, and international expansion to UAE and UK.
FDA Regulatory Pathways for Brain-Computer Interface Devices — IDE, Breakthrough, and De Novo
Detailed guide to the FDA regulatory framework for BCI devices, covering Investigational Device Exemptions, Breakthrough Device designation, De Novo classification, and premarket approval.
Synchron Stentrode — The Endovascular Brain-Computer Interface Approach
Analysis of Synchron's Stentrode BCI system, its minimally invasive endovascular delivery, integration with NVIDIA AI and Apple Vision Pro, and the Chiral cognitive AI roadmap.
Non-Invasive BCI Technologies — EEG, fNIRS, and the 81.9% Market Majority
Analysis of non-invasive brain-computer interface technologies that dominate 81.86% of the BCI market, examining EEG-based systems, functional near-infrared spectroscopy, and consumer neurotechnology.